AQR Capital Management’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-21,152
| Closed | -$708K | – | 3955 |
|
|
2026
Q1 | $708K | Sell |
21,152
-37,600
| -64% | -$1.47M | ﹤0.01% | 2957 |
|
|
2025
Q4 | $2.72M | Buy |
58,752
+21,655
| +58% | +$1.19M | ﹤0.01% | 1944 |
|
|
2025
Q3 | $2.51M | Buy |
37,097
+33,441
| +915% | +$2.48M | ﹤0.01% | 1846 |
|
|
2025
Q2 | $306K | Buy |
3,656
+543
| +17% | +$40.6K | ﹤0.01% | 2866 |
|
|
2025
Q1 | $222K | Sell |
3,113
-7,635
| -71% | -$372K | ﹤0.01% | 2835 |
|
|
2024
Q4 | $483K | Sell |
10,748
-1,530
| -12% | -$79.3K | ﹤0.01% | 2267 |
|
|
2024
Q3 | $620K | Buy |
+12,278
| New | +$588K | ﹤0.01% | 2072 |
|
|
2024
Q2 | – | Sell |
-6,792
| Closed | -$291K | – | 2673 |
|
|
2024
Q1 | $291K | Buy |
+6,792
| New | +$307K | ﹤0.01% | 2139 |
|
|
2021
Q1 | – | Sell |
-3,929
| Closed | -$114K | – | 2261 |
|
|
2020
Q4 | $114K | Sell |
3,929
-2,976
| -43% | -$85.9K | ﹤0.01% | 2146 |
|
|
2020
Q3 | $260K | Buy |
+6,905
| New | +$202K | ﹤0.01% | 1972 |
|
AQR Capital Management's SLNO Position: Q2 2026 in Review
AQR Capital Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 21,152 shares — an estimated $708K sold.
AQR Capital Management first reported a position in SLNO in Q3 2020 and held it in 10 quarters. The position peaked at $2.72M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- AQR Capital Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- AQR Capital Management sold 21,152 Soleno Therapeutics shares in Q2 2026, an estimated $708K.
- AQR Capital Management first reported a position in Soleno Therapeutics in Q3 2020 and held it in 10 quarters.
- AQR Capital Management's Soleno Therapeutics position peaked at $2.72M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.